We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+4.56%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.67B
AUM Growth
+$41.2M
Cap. Flow
+$7.87M
Cap. Flow %
0.29%
Top 10 Hldgs %
35.39%
Holding
233
New
11
Increased
50
Reduced
32
Closed
29

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$32.1M
2
ILMN icon
Illumina
ILMN
+$23.5M
3
STE icon
Steris
STE
+$18.5M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$16.2M
5
HUM icon
Humana
HUM
+$15.1M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$41.9M
2
TMO icon
Thermo Fisher Scientific
TMO
+$31.6M
3
UNH icon
UnitedHealth
UNH
+$29M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$21M
5
CVS icon
CVS Health
CVS
+$20.6M

Sector Composition

Rank Sector Weight
1 Healthcare 95.21%
2 Real Estate 2.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLDX icon
201
Celldex Therapeutics
CLDX
$2.96B
$105K ﹤0.01%
7,053
– –
BLCM
202
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$39K ﹤0.01%
6,000
– –
MNK
203
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$32K ﹤0.01%
32,980
– –
ALLO icon
204
Allogene Therapeutics
ALLO
$635M
– –
-216,069
Closed -$9.25M
ANAB icon
205
AnaptysBio
ANAB
$1.59B
– –
-118,261
Closed -$2.64M
BBIO icon
206
BridgeBio Pharma
BBIO
$15.7B
– –
-39,228
Closed -$1.28M
CDTX
207
DELISTED
Cidara Therapeutics
CDTX
– –
-9,763
Closed -$720K
EDIT icon
208
Editas Medicine
EDIT
$407M
– –
-130,201
Closed -$3.85M
EVH icon
209
Evolent Health
EVH
$353M
– –
-231,027
Closed -$1.65M
HALO icon
210
Halozyme
HALO
$9.76B
– –
-69,917
Closed -$1.87M
INO icon
211
Inovio Pharmaceuticals
INO
$72M
– –
-16,837
Closed -$5.45M
KOD icon
212
Kodiak Sciences
KOD
$2.49B
– –
-23,153
Closed -$1.25M
LGND icon
213
Ligand Pharmaceuticals
LGND
$5.85B
– –
-49,036
Closed -$3.42M
NTLA icon
214
Intellia Therapeutics
NTLA
$1.5B
– –
-55,050
Closed -$1.16M
PACB icon
215
Pacific Biosciences
PACB
$441M
– –
-495,495
Closed -$1.71M
PBYI icon
216
Puma Biotechnology
PBYI
$391M
– –
-71,340
Closed -$744K
PTCT icon
217
PTC Therapeutics
PTCT
$5.68B
– –
-120,827
Closed -$6.13M
RCKT icon
218
Rocket Pharmaceuticals
RCKT
$376M
– –
-289,029
Closed -$6.05M
SGMO
219
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-149,835
Closed -$1.34M
WVE icon
220
Wave Life Sciences
WVE
$1.13B
– –
-128,146
Closed -$1.33M
TECX
221
Tectonic Therapeutic
TECX
$527M
– –
-11,715
Closed -$2.45M
WHWK
222
Whitehawk Therapeutics
WHWK
$196M
– –
-17,170
Closed -$322K
RUBY
223
DELISTED
Rubius Therapeutics, Inc
RUBY
– –
-155,982
Closed -$933K
QTNT
224
DELISTED
Quotient Limited Ordinary Shares
QTNT
– –
-10,298
Closed -$3.05M
EPZM
225
DELISTED
Epizyme, Inc
EPZM
– –
-207,752
Closed -$3.34M
6 7 8
9
10

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Tekla Capital Management held 233 positions worth $2.67B, up 1.6% from $2.63B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Tekla Capital Management's Q3 2020 filing shows 11 new, 50 increased, 32 reduced and 29 closed positions. Its largest new stake was ChemoCentryx, Inc.: 144,447 shares worth $7.92M. The largest sale was Johnson & Johnson, an estimated $41.9M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2020 buy was ChemoCentryx, Inc.: 144,447 shares worth $7.92M.
  • Tekla Capital Management added most to AbbVie in Q3 2020, an estimated $32.1M increase.
  • Tekla Capital Management's biggest Q3 2020 reduction was Johnson & Johnson, cutting an estimated $41.9M.
  • Tekla Capital Management fully exited Allogene Therapeutics in Q3 2020, selling an estimated $9.25M.
  • Tekla Capital Management's ten largest holdings make up 35% of its $2.67B portfolio in Q3 2020.
  • Tekla Capital Management opened 11 new positions and closed 29 in Q3 2020.
  • Tekla Capital Management's portfolio value rose 1.6% quarter-over-quarter to $2.67B.

Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.